Overview

Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Multi-center, parallel-group, randomized, open control study. All patients will be selected to two treatment groups. 1. Etanercept alone treatment group (25mg, twice/week, s.c.) 2. Etanercept combined with MTX group (25mg, twice/week, s.c.+MTX 6-8mg/week)
Phase:
Phase 4
Details
Lead Sponsor:
Japan Biological Agent Study Integrated Consortium
Treatments:
Etanercept
Methotrexate